UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

SUBMIT
Already an Engineering360 user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your Engineering360 Experience

Finish!
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

CLSI - NBS09

Newborn Screening for X-Linked Adrenoleukodystrophy

active, Most Current
Organization: CLSI
Publication Date: 1 August 2021
Status: active
Page Count: 100
scope:

This guideline discusses the detection of X-linked adrenoleukodystrophy (ALD) by population-based newborn dried blood spot (DBS) screening. It focuses on high-throughput flow injection analysis-tandem mass spectrometry (FIA-MS/MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods for detecting C26:0-lysophosphatidylcholine (LPC), the primary biomarker for ALD. This guideline is intended to provide information for incorporating ALD newborn DBS screening into the routine operations of existing newborn screening (NBS) programs.

NBS09 includes background information on the biological and clinical features of ALD, the most common peroxisomal disorder, as well as other disorders of peroxisomal fatty acid oxidation, such as the Zellweger spectrum disorders (ZSDs), that could also be identified by ALD NBS. It describes preanalytical factors that affect ALD screening, including newborn DBS collection timing and specimen storage and stability. In addition to providing details on the different tandem mass spectrometry (MS/MS) analytical methods for C26:0-LPC, this guideline discusses screening strategies, testing algorithms, cutoff value determination, case definition, and risk assessment for NBS programs to consider when implementing X-linked ALD NBS.

The intended users of this guideline are NBS laboratory, follow-up, and program personnel, public health program administrators, diagnostic medical laboratories and ALD treatment centers, health care providers (HCPs) (eg, primary care providers, neonatologists, pediatricians), regulatory agencies, public health policy makers, and manufacturers of instruments, reagents, and related products used for NBS testing.

NBS09 discusses postanalytical short-term follow-up (STFU) and long-term follow-up (LTFU) procedures, including case tracking, as well as the diagnostic tests needed to confirm an ALD diagnosis and special follow-up considerations associated with screening for a disease with a long latency period. It contains limited discussion on diagnosis and follow-up of ZSDs and other disorders of peroxisomal fatty acid oxidation that may also be identified by ALD screening. This guideline does not cover:

• DBS specimen collection for ALD NBS (see CLSI document NBS016)

• Details of confirmatory diagnostic laboratory testing

- Methods for measuring very long-chain fatty acids (VLCFA) in plasma to confirm positive ALD newborn DBS screening results

- Methods for ABCD1 variant analysis to confirm positive ALD newborn DBS screening results

• Guidelines for diagnosis or treatment of ALD

Document History

NBS09
August 1, 2021
Newborn Screening for X-Linked Adrenoleukodystrophy
This guideline discusses the detection of X-linked adrenoleukodystrophy (ALD) by population-based newborn dried blood spot (DBS) screening. It focuses on high-throughput flow injection...

References

Advertisement